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Background: To evaluate the analgesic efficacy of bromfenac sodium ophthalmic solution 
0.09% compared with ketorolac tromethamine ophthalmic solution 0.5% in laser epithelial 
keratomileusis (LASEK) or epithelial keratomileusis (epi-LASEK), sometimes referred to as 
epi-LASIK.
Methods: Eighty eyes (from 40 patients, 18 men and 22 women) undergoing bilateral 
simultaneous LASEK or epi-LASEK were randomized to receive ketorolac in one eye and 
bromfenac in the other. Mean age was 33.13 ± 9.34 years. One drop of bromfenac or ketorolac 
was instilled in each eye 15 minutes and one minute prior to surgery, and two and four hours 
following surgery. Patients were instructed to instill the medications on-label each day through 
postoperative day 4. The subjects completed pain and visual blurriness assessments from 
day of surgery to postoperative day 4. Uncorrected visual acuity was tested on postoperative 
days 1 and 6.
Results: For each of the five days, pain scores for bromfenac-treated eyes were significantly 
less than that for ketorolac-treated eyes (P , 0.01). Of the 40 patients, 32 (80%) said bromfenac 
provided better postoperative analgesia than ketorolac. There was no statistically significant 
difference in visual blurriness scores between the two groups (P . 0.1). Uncorrected visual 
acuity did not vary significantly between the treatment groups (P . 0.1). No serious adverse 
events were noted.
Conclusion: Bromfenac is subjectively superior to ketorolac in reducing postoperative pain 
following LASEK or epi-LASEK. The subjects tolerated the drugs well with no serious adverse 
outcomes and no difference in uncorrected visual acuity.
Keywords: LASEK, epi-LASEK, epi-LASIK, ketorolac, bromfenac, postoperative pain, non-
steroidal anti-inflammatory drugs
Introduction
Laser refractive surgery has gone through several phases, beginning in the 1990s with 
photorefractive keratectomy. In photorefractive keratectomy, the cornea is reshaped to 
correct ametropia by removing corneal epithelial cells via a brush, which then leaves 
an irregular surface. Unfortunately, this technique often resulted in discomfort and 
pain that persisted beyond 48 hours.1
Subsequently, the procedure of laser-assisted in situ keratomileusis (LASIK) 
was developed. In LASIK a flap in the corneal stroma is created in lieu of removing 
epithelial cells. In 1999, laser epithelial keratomileusis (LASEK) was   introduced to 
eliminate the flap-related complications of LASIK. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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In LASEK, the epithelium is first loosened by ethanol, 
then rolled to the periphery before laser treatment on the 
stroma. The epithelium is subsequently placed back on the 
stroma. Patients undergoing LASEK have been reported to 
have a lower risk of postoperative ectasia, indicating that the 
surface treatment may be safer.2
Epithelial LASEK, or epi-LASEK, sometimes referred to 
as LASIK, is the latest surface ablation treatment, combining 
LASIK, LASEK, and photorefractive keratectomy. Epi-
LASEK uses an epikeratome for planar separation of the 
epithelium, thereby keeping Bowman’s membrane intact. 
The goal of this planar separation is to reduce healing time, 
which may decrease patient discomfort.3 In epi-LASEK, the 
epithelium is rolled to the periphery and replaced after laser 
treatment (similarly to LASEK).
Regardless of which refractive surgical technique is used, 
they will all cause injury to the corneal sensory nociceptive 
fibers, which can then lead to various degrees of pain.1 
Chemical mediators, such as prostaglandins, are released 
during ocular surgery and also contribute to postoperative 
pain. The pain created from the corneal wound and chemical 
mediators can be mitigated by bandage contact lenses and 
oral and topical analgesia. In ophthalmology, the primary 
topical analgesia used for the control of pain is nonsteroidal 
anti-inflammatory drugs (NSAIDs).4–6
Nonsteroidal anti-inflammatory drugs
Ocular surgery creates inflammation caused by the 
conversion of arachidonic acid to prostaglandin by cyclo-
oxygenase (COX). As a class, NSAIDs are accepted 
as having the ability to inhibit COX, thereby reducing 
inflammation.7,8 Rowen reported that the preoperative 
administration of an NSAID will have its maximum anal-
gesic effect in the early postoperative phase, when the pain 
is most intense.9
Several clinical studies have shown that topical 
ophthalmic NSAIDs are effective in controlling pain 
associated with refractive laser vision correction, cataract 
surgery, and corneal abrasions.7,10–19 There are several 
topical ophthalmic NSAIDs in branded and generic 
formulations currently available in the US. Two of the most 
commonly used NSAIDs are bromfenac and ketorolac. 
Bromfenac sodium ophthalmic solution 0.09% (Xibrom®, 
ISTA Pharmaceuticals Inc, Irvine, CA) has been shown 
to be safe and effective in controlling pain following 
photorefractive keratectomy,16,20 cataract surgery,11,21,22 and 
corneal abrasions.23 Ketorolac tromethamine ophthalmic 
solution 0.5% (Acular®, Allergan Inc, Irvine, CA) 
has been shown to be safe and effective in controlling 
pain following photorefractive keratectomy,12,17 radial 
keratotomy,19 corneal abrasion,13 and cataract surgery.14 
In addition, ketorolac 0.5% has been shown to reduce 
corneal sensitivity significantly.15 This study compared 
the safety and efficacy of bromfenac sodium ophthalmic 
solution 0.09% and ketorolac tromethamine ophthalmic 
solution 0.5% in managing ocular pain following LASEK 
or epi-LASEK.
Materials and methods
Patients
A total of 40 patients were enrolled in the study. Subjects had 
to be at least 18 years old and scheduled to undergo bilateral 
simultaneous LASEK (n = 32) or epi-LASEK (n = 8). Other 
inclusion criteria included: a difference in prescription in both 
eyes not exceeding 3 diopters (D); best corrected visual acuity 
of at least 20/25; completion of a self-assessment pain report; 
anticipated return for all required study visits; and predicted 
compliance with all instructions. Patients were excluded if 
they were taking either topical or systemic NSAIDs, were 
taking and/or had taken either of the investigational drugs 
within 45 days of surgery, and/or were taking any kind of 
blood thinner. Pregnant women, nursing mothers, or mothers 
of infants younger than six months of age were excluded 
from the study.
In addition, patients were excluded if they had any 
systemic or ocular disease that might interfere with proper 
wound healing, such as a history of ocular trauma, uveitis, 
ocular infection and/or inflammation, anemia, diabetes 
mellitus, rheumatoid arthritis, and/or pulmonary disease 
other than reactive airways disease. Patients who had a 
history of alcohol abuse, tobacco use (smoking more than 
one pack of cigarettes per day), or drug abuse, as well as 
those with a history of sensitivity to sulfites or NSAIDs, 
were excluded.
Study design
This study was a prospective, randomized, single-center 
study. All surgeries were performed by one surgeon (EWC). 
An independent investigational review board (IRB Inc, 
Plantation, FL) approved the project, and informed consent 
was obtained from the subjects after the nature of procedures 
had been explained. ISTA Pharmaceuticals Inc provided 
ketorolac tromethamine ophthalmic solution 0.5% and 
bromfenac sodium ophthalmic solution 0.09% free of charge 
for this study and monetary compensation to the subjects to 
encourage participation.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Test articles and dose regimen
Patients were screened 7–30 days prior to surgery. Each right 
eye was randomized to receive either ketorolac tromethamine 
ophthalmic solution 0.5% or bromfenac sodium ophthalmic 
solution 0.09%. Each left eye was assigned to receive the 
NSAID alternative to the NSAID to which the right eye 
was randomized. For example, if the right eye was assigned 
to receive ketolorac, the left eye was assigned to receive 
bromfenac, and vice versa. On the day of surgery, one drop of 
bromfenac or ketorolac was instilled in each eye 15 minutes 
and one minute prior to surgery and two and four hours 
following surgery.
Patients were given vials marked by right and left 
eye indicators and by number 1 through number 4. For 
postoperative days 1 and 2, patients were instructed to 
instill the drops in the designated eye in the correct vial 
order (from number 1 through number 4) upon waking, at 
noon, at dinner time, and before bed, as shown in Table 1. 
To mask patients to the medications, each eye was instilled 
four times a day. For the ketorolac-treated eye, all vials 
contained ketorolac and were dosed on-label (one drop four 
times daily). For the bromfenac-treated eye, vials 1 and 3 
contained bromfenac, and vials 2 and 4 contained a placebo 
(Refresh Plus® artificial tears, Allergan Inc), because on-label 
bromfenac use is one drop two times daily. For postoperative 
day 3 and day 4, the subjects were asked to only use vials 1 
and 2 upon waking and at dinner time in order to taper the 
NSAIDs to half their dosages. The subjects were instructed 
to use labeled preservative-free artificial tears every hour in 
between instilling drops from the numbered vials to maintain 
lubrication of both eyes and facilitate epithelial healing.
All other postoperative drug regimens were identical 
for both eyes. These included: one drop twice daily of 
antibiotic; one drop twice daily of prednisolone acetate 
ophthalmic suspension (Pred Forte®, Allergan Inc); oral 
methylprednisolone (Medrol Dosepak®, Pfizer Inc, New 
York, NY) according to tapering directions on the back 
of the blister pack (subjects with high prescription, for 
example, $−6 D or $−3 D cylinder, took two packs on 
alternating days); 400 mg of gabapentin (Neurontin®, Pfizer 
Inc) daily through postoperative day 3; and vitamin C 
500 mg twice daily for three months. Topical antibiotics were 
prescribed as part of the surgeon’s regular postoperative care, 
which were levofloxacin ophthalmic solution 0.5% (Quixin®, 
Vistakon Pharmaceuticals Inc, Jacksonville, FL), gatifloxacin 
ophthalmic solution 0.3% (Zymar®, Allergan Inc), or 
moxifloxacin HCl ophthalmic solution 0.5% (Vigamox®, 
Alcon Laboratories Inc, Fort Worth, TX). Subjects applied 
the same antibiotic to each eye.
Surgical technique
Bilateral LASEK or epi-LASEK was performed by a single 
surgeon (EWC) using the VISX Star S4 IR Excimer Laser 
System (Abbott Laboratories Inc, Abbott Park, IL). Before 
surgery, topical tetracaine 0.5%, prednisolone acetate 
ophthalmic suspension 1% (EconoPred Plus®, Alcon), and 
levofloxacin ophthalmic solution 1.5% were applied once 
to each eye. Alcohol-assisted separation for LASEK was 
performed by application of 50% ethanol in a trephine well 
for 10 seconds, followed by rinsing of the eye with balanced 
salt solution and epithelial separation using a hockey spatula. 
Mechanical separation of the epithelium for epi-LASIK was 
performed by application of 50% ethanol in a trephine well 
for five seconds, followed by rinsing of the eye with balanced 
salt solution and epithelial separation using an epikeratome 
(Norwood EyeCare, Duluth, GA).
After stromal ablation was performed, 0.1% mitomycin C 
was applied on a cellulose sponge on the ablated corneal bed 
for high myopes (.−6 D) for a time equal to the laser ablation 
time. Topical prednisolone acetate and levofloxacin were 
applied once before a bandage contact lens (Acuvue Moist®, 
Johnson & Johnson Vision Care Inc, New Brunswick, NJ) 
was applied to the operated eye. Subjects were asked to 
refrain from using pain suppressants (escape medication), 
such as oral NSAIDs and/or narcotics. Ultraviolet protection 
was mandated postoperatively for three months to prevent 
scarring.
Efficacy outcome measures
Subjects completed a self-assessment questionnaire from day 
of surgery to postoperative day 4. On each day, the question-
naire asked the subject to evaluate the pain level and the visual 
Table 1 Topical NSAID dose regimen on postoperative days 1 and 2
Waking Noon Dinner time Before bed
Bromfenac-treated  
eye
Vial 1:  
Bromfenac
Tears every hour Vial 2:  
Placebo
Tears every hour Vial 3:  
Bromfenac
Tears every hour Vial 4:  
Placebo
Ketorolac-treated  
eye
Vial 1:  
Ketorolac
Tears every hour Vial 2:  
Ketorolac
Tears every hour Vial 3:  
Ketorolac
Tears every hour Vial 4:  
KetorolacClinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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blurriness in each eye based on the following scale: 0 = none, 
1 = minimal, 2 = moderate, 3 = severe, and 4 = extreme. The 
questionnaire did not extend to postoperative day 6, when 
the patient returned to the clinic, because the NSAIDs were 
only instilled up to postoperative day 4. Moreover, it was 
preferable that the pain and visual blurriness scores were 
self-assessed before the postoperative day 6 visit to eliminate 
potential influence by the study coordinators.
The questionnaire was returned at the postoperative day 6 
visit. Each patient was evaluated in the office on postopera-
tive day 1 and day 6. Each patient was asked what medica-
tions were taken and at what dose to confirm compliance. 
Uncorrected visual acuity was also measured for each eye.
Efficacy analysis and statistical methods
The results were based on the total number of patients 
who completed all aspects of the study without premature 
termination. The Wilcoxon Signed-Rank test was performed 
to compare the pain scores and the visual blurriness scores 
between bromfenac-treated and ketorolac-treated eyes 
for each day. Characteristics, such as degree of myopia/
hyperopia, degree of astigmatism, spherical equivalent, 
ablation depth, and uncorrected visual acuity in logMAR 
between bromfenac-treated and ketorolac-treated eyes, were 
compared using the paired Student’s t-test.
Safety outcome measures
During the office visits on postoperative day 1 and day 6, any 
complaints, such as dry eyes and irritation, were noted. A slit 
lamp examination was performed on each eye to confirm the 
presence of the bandage contact lens and to look for any cor-
neal changes. On postoperative day 6, if the epithelium had 
healed, the bandage contact lenses were removed; otherwise, 
patients were given additional analgesics and were excluded 
from the study.
Results
One hundred eyes from 50 patients were initially enrolled 
in the study. Ten patients (20 eyes) were excluded from the 
study because patient-induced premature bandage contact 
lens removal from one or both eyes resulted in the need for 
escape medication(s). The mean average age of the per protocol 
cohort was 33.13 ± 9.34 years. There were no statistically 
significant surgical treatment differences between the two 
groups, as shown in Table 2. This was expected because the 
characteristics and treatments of two eyes from the same 
person are expected to be almost identical. Overall, in each 
group, 80% of the eyes underwent LASEK, 20% underwent 
epi-LASEK, and 75% were given mitomycin C. No subject had 
an immediate postoperative pain score that differed by more 
than one point, demonstrating that the two eyes were similar 
enough in postoperative pain to use as matched controls.
Postoperative pain relief and blurriness 
scores
Patients assessed their pain and blurriness levels (using a 
scale from 0 to 4) daily in the clinic, from day of surgery 
through postoperative day 4. Eighty percent (32 of 40) of 
patients reported less pain in bromfenac-treated eyes than 
in ketorolac-treated eyes, as shown in Figure 1. Blurriness 
score differences did not reach statistical significance on 
any day, as shown in Figure 2. On the day of surgery, mean 
pain levels were 1.39 ± 0.19 in the ketorolac-treated eye and 
0.74 ± 0.16 in the bromfenac-treated eye (P = 0.0002). Mean 
blurriness levels were 0.90 ± 0.19 in the ketorolac-treated 
eye and 0.88 ± 0.19 in the bromfenac-treated eye (P . 0.1). 
On postoperative day 1, mean pain levels were 1.36 ± 0.18 in 
the ketorolac-treated eye, and 0.85 ± 0.17 in the bromfenac-
treated eye (P = 0.0035). Mean blurriness levels were 
1.06 ± 0.18 in the ketorolac-treated eye and 1.03 ± 0.18 in 
the bromfenac-treated eye (P . 0.1). On postoperative 
day 2, mean pain levels were 1.19 ± 0.17 in the ketorolac-
treated eye and 0.78 ± 0.17 in the bromfenac-treated eye 
(P = 0.0011). Mean blurriness levels were 0.87 ± 0.16 in 
the ketorolac-treated eye and 0.82 ± 0.15 in the bromfenac-
treated eye (P . 0.1). On postoperative day 3, mean pain 
levels were 1.05 ± 0.16 in the ketorolac-treated eye and 
0.60 ± 0.14 in the bromfenac-treated eye (P = 0.0023). Mean 
blurriness levels were 0.87 ± 0.16 in the ketorolac-treated 
eye and 0.82 ± 0.15 in the bromfenac-treated eye (P . 0.1). 
Table 2 Participant characteristics
Demographics n (%)
Male 18 (45)
Female 22 (55)
Ketorolac- 
treated eye
Bromfenac- 
treated eye
P value
n = 40 n = 40
Mean ± SD Mean ± SD
Degree of myopia/ 
hyperopia (preop)
−4.81 ± 3.81 −4.86 ± 3.73 0.8
Degree of astigmatism  
(preop)
−1.34 ± 0.85 −1.26 ± 0.83 0.62
Spherical equivalent  
(preop)
−5.48 ± 3.76 −5.49 ± 3.75 0.95
Ablation depth  
(in microns)
  76.4 ± 43.1   79.4 ± 40.0 0.46
Abbreviations: preop, preoperative; SD, standard deviation.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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On postoperative day 4, mean pain levels were 0.75 ± 0.15 in 
the ketorolac-treated eye and 0.29 ± 0.11 in the bromfenac-
treated eye (P = 0.0008). Mean blurriness levels were 
0.60 ± 0.13 in the ketorolac-treated eye and 0.64 ± 0.13 in 
the bromfenac-treated eye (P . 0.1).
Efficacy of bromfenac and ketorolac  
on visual acuity
Uncorrected visual acuity was measured for each eye on 
postoperative day 1 and day 6. Data were converted to 
logMAR before statistical analysis. The uncorrected visual 
acuity in the ketorolac-treated eye was 0.50 ± 0.04 logMAR 
and 0.45 ± 0.04 in the bromfenac-treated eye on postoperative 
day 1, and 0.26 ± 0.03 and 0.28 ± 0.03, respectively, on 
postoperative day 6. These differences were not statistically 
significantly different.
Adverse events
There were no serious adverse events reported. In both sets 
of eyes, 20% (n = 8) reported temporary dry eye, and 5% 
(n = 2) reported temporary irritation. On postoperative day 6, 
epithelial regeneration was complete for all eyes in the study, 
thus permitting removal of bandage contact lenses during 
the clinic visit.
Ketolorac-treated eyes Bromfenac-treated eyes
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Figure 1 Pain scores of ketorolac-treated eyes vs. bromfenac-treated eyes.
Note: Error bar = standard error
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Figure 2 Visual blurriness scores of ketorolac-treated eyes vs. bromfenac-treated eyes.
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Discussion
Because the cornea is one of the most densely innervated 
tissues in the eye, it is also the most sensitive to pain.24 Each 
successive advancement in laser vision correction has sought 
to diminish postoperative pain, among other things. In LASIK, 
this postoperative pain is caused by the combination of corneal 
epithelial layer disruption and wound creation via the inci-
sion.5 In LASEK and epi-LASEK, the pain is caused by the 
use of 50% ethanol solution in LASEK and an epikeratome in 
epi-LASEK to separate the epithelium at Bowman’s layer.25,26 
Comparing the latter two procedures, epi-LASEK produces 
less postoperative pain than LASEK.3
This study examined the efficacy of two marketed 
NSAID ophthalmic solutions in their abilities to relieve pain 
following either epi-LASEK or LASEK surgery. The use of 
bromfenac 0.09% or ketorolac 0.5% for postoperative pain 
relief after laser vision correction surgery has been well 
documented.16,20,27,28 In this study, bromfenac 0.09% was 
found to be more effective in reducing overall postoperative 
pain than ketorolac 0.5%. The authors did not find any 
statistically significant differences in visual blurriness, 
uncorrected visual acuity, or adverse events between the two 
treatment groups. Stromal and epithelial variations between 
epi-LASEK procedures were eliminated by the application 
of 50% ethanol in a trephine well for five seconds, which 
loosened the corneal epithelial cells before the microkeratome 
was used for separation.
All topical NSAIDs work by eliminating the ability 
of COX-1 and COX-2 to produce prostaglandin.29 In oral 
form, bromfenac has been shown to have superior potency 
when compared with other NSAIDs, with no systemic side 
effects.30,31 In its topical form, bromfenac has been shown to 
have enhanced intraocular penetration and distribution in the 
cornea, iris, ciliary body, retina, and choroids, along with a 
longer duration of action that may last for up to 24 hours at 
these sites.8,23,32–34 Bromfenac has been cited as being more 
selective toward COX-2, with ketorolac being more selec-
tive towards COX-1.35–37 The inhibition of COX-2 has been 
associated with therapeutic effects of NSAIDs more than 
COX-1, in vivo and in humans.36,38,39 COX-1 is expressed 
in most tissues and organs, whereas COX-2 expression is 
localized primarily to inflammatory cells and tissues.40
Data have shown that inhibition of COX-2 was enough 
to produce a maximum analgesic effect in response to 
  prostaglandin production.36,38 Our findings support the theories 
in those previously published studies, because bromfenac-
treated eyes were subjectively evaluated to be less painful in 
the postoperative period than ketorolac-treated eyes.
Although this study was not double-masked, the patients 
evaluated the drugs in terms of pain and visual blurriness 
on their own in the absence of the study coordinators. 
Questionnaire responses were subjective and involved self-
reported analysis of pain in both eyes individually, thereby 
eliminating potential biases. Even though the sample size 
was small (n = 80), the authors were able to show significant 
differences in pain scores between the treatment groups.
The authors suggest conducting future studies to 
determine whether inhibition of COX-1 or COX-2 reduces 
postoperative ocular inflammation and pain more effectively 
after epi-LASEK or LASEK. The authors also suggest that 
newer, commercially available ocular NSAIDs, such as once-
daily bromfenac ophthalmic solution 0.09% (Bromday®, 
ISTA Pharmaceuticals Inc), ketorolac 0.4% or ketorolac 
0.45% (Acular LS® and Acuvail®, respectively, Allergan 
Inc), and nepafenac ophthalmic suspension 0.1% (Nevanac®, 
Alcon Laboratories Inc) be evaluated for their analgesic 
capabilities after epi-LASEK or LASEK.
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